Alumis to Present at the Leerink Partners Global Healthcare Conference
Alumis (Nasdaq: ALMS) announced that CEO Martin Babler will speak at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
Rhea-AI Summary
Alumis (Nasdaq: ALMS) announced that CEO Martin Babler will speak at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET. A live webcast will be available on the company's Investors > Events page, and a replay will be archived for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ALMS
On Mar 2, the day this news came out, ALMS closed 0.10% above the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Conference date
- March 9, 2026
- Leerink Partners Global Healthcare Conference fireside chat
- Presentation time
- 10:40 a.m. ET
- Scheduled start time of Alumis fireside chat
- Webcast replay period
- 90 days
- Length of time replay will be archived on company website
Historical Context
-
Planned participation in two February 2026 investor conferences with webcasts.
-
Closing of upsized underwritten public offering and full exercise of underwriters’ option.
-
Pricing of upsized underwritten public offering of common stock under existing shelf.
-
Announcement of proposed underwritten public offering of common stock.
-
Positive topline Phase 3 envudeucitinib data in plaque psoriasis with strong efficacy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET.
A live webcast will be available on the Alumis website in the “Investors” section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.